Bafilomycin A1[1]
IUPAC name
(3Z,5E,7R,8S,9S,11E,13E,15S,16R)-16- [(1S,2R,3S)-3-[(2R,4R,5S,6R)-2,4-dihydroxy-6- isopropyl-5-methyl-2-tetrahydropyranyl]-2- hydroxy-1-methylbutyl]-8-hydroxy-3,15- dimethoxy-5,7,9,11-tetramethyl-1- oxacyclohexadeca-3,5,11,13-tetraen-2-one
88899-55-2 N
ChemSpider 10251049 YesY
DrugBank DB06733 YesY
ECHA InfoCard 100.150.187
PubChem 6436223
Molar mass 622.83 g/mol
Appearance Yellow powder
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N verify (what is YesYN ?)
Infobox references

The bafilomycins are a family of toxic macrolide antibiotic derived from Streptomyces griseus. These compounds all appear in the same fermentation and have quite similar biological activity. Bafilomycins are specific inhibitors of vacuolar-type H+-ATPase.

The most used bafilomycin is bafilomycin A1. This is a useful tool as it can prevent the re-acidification of synaptic vesicles once they have undergone exocytosis.

Bafilomycin has antibacterial, antifungal, antineoplastic, immunosuppressive activities. In addition, bafilomycin A1 has antimalarial activity [2] It has been shown to decrease multi-drug resistance.

Bafilomycin B1 has been mentioned as a potential antiosteoporotic agent in treating bone lytic diseases.


  1. Bafilomycin A1 product page from Fermentek
  2. van Schalkwyk DA, Chan XW, Misiano P, Gagliardi S, Farina C, Saliba KJ. "Inhibition of Plasmodium falciparum pH regulation by small molecule indole derivatives results in rapid parasite death" Biochem Pharmacol. 2010 May 1;79(9):1291-9. PMID 20067768
This article is issued from Wikipedia - version of the 11/16/2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.